Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542

Japan

Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

EP Vantage Pharma & Biotech 2014 in Review

EP Vantage Pharma & Biotech 2014 in Review

Download EP Vantage Pharma & Biotech 2014 in Review

Despite a wobble in the spring, the pharma and biotech sector came back stronger than ever, racking up a record-breaking $212 billion in M&A transactions.  

The feel good factor also extended to IPOs. Largely fuelled by investor appetite for immunotherapy, 2014 boasted 87 flotations, raising a combined $6.3 billion, one of the best hauls since the genomic bubble of 2000.

LISTEN: Amy Brown, News Editor, EP Vantage joins FierceBiotech Radio to talk about her retrospective look at a big year for biotech and peek ahead at what might be in store for 2015.

Key highlights include:

  • Specialty pharma M&A frenzy, including the $66 billion purchase of Allergan, helped drive the $212 billion in M&A transactions; eclipsing the $152 billion spent in 2009
  • IPO filings doubled from 44 in 2013 to 87 in 2014; total amount raised jumped from $2.9 billion to $6.3 billion
  • UK-based biopharma company, Circassia, broke IPO records with $332 million debut
  • Venture capital funding rose by 33% to $6.5 billion
  • FDA drug approvals rose 43% from 2013 with impressive tally of 50 new drugs
  • Eli Lilly was the best performing big pharma stock in 2014 with shares up 35%
  • GlaxoSmithKline was the worst performing stock with shares down 15% in the year

Download EP Vantage Pharma & Biotech 2014 in Review

Press Release

Related Reports: 

EP Vantage MedTech 2014 in Review 

EvaluatePharma Japan Sales Volume Pricing 2015

EP Vantage CAR-T Therapy Landscape in 2015

EP Vantage Pharma & Biotech 2015 Preview